The Board of Pharmacy has received notice of the following product recall. The Board strongly encourages pharmacies to immediately review their quality assurance and recall policies and procedures to determine if any corrective action is required.

Mylan Institutional Inc. (MII) is conducting a recall at the retail level of the below listed batches of Levothyroxine Sodium Tablets, USP, repackaged by MII in unit dose UD100. These batches are being recalled out of an abundance of caution due to corresponding assay results that are out of specification. The batches were distributed in the US between February 27, 2024 and December 16, 2024.

The potential risk to patients arising from this issue is considered to be negligible and, to date, no reports of adverse reactions associated with these lots have been received. Levothyroxine Sodium Tablets USP, is indicated in adult and pediatric patients, including neonates, for hypothyroidism and pituitary thyrotropin (thyroid-stimulating hormone, TSH) suppression.

Product, Strength, & Form	NDC Number	Size	MII Batch Number	MII Expiration Date
Levothyroxine Sodium Tablets, USP 125 mcg	51079-443-20	UD100	3115773	3/2025
Levothyroxine Sodium Tablets, USP 150 mcg	51079-445-20	UD100	3116074	9/2025